NASDAQ:QTNTQuotient Stock Price, Forecast & News

Quotient's stock was trading at $4.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, QTNT shares have increased by 60.6% and is now trading at $7.45. View which stocks have been most impacted by Coronavirus.

Quotient is scheduled to release its next quarterly earnings announcement on Tuesday, June 9th 2020. View our earnings forecast for Quotient.

Quotient will be holding an earnings conference call on Tuesday, June 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Quotient Ltd (NASDAQ:QTNT) announced its quarterly earnings results on Thursday, January, 30th. The company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.04. The company earned $7.94 million during the quarter, compared to analyst estimates of $7.10 million. View Quotient's earnings history.

Press coverage about QTNT stock has trended positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Quotient earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutQuotient.

Some companies that are related to Quotient include Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Heska (HSKA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Vermillion (VRML), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), ImmuCell (ICCC), GeneNews (GNWSF), Akers Biosciences (AKER) and Achieve Life Sciences (ACHV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Verastem (VSTM), Gilead Sciences (GILD), Novavax (NVAX), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Ocular Therapeutix (OCUL) and Clovis Oncology (CLVS).

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Quotient's stock is owned by many different institutional and retail investors. Top institutional shareholders include Cormorant Asset Management LP (3.94%), Clearbridge Investments LLC (3.80%), TimesSquare Capital Management LLC (3.64%), Morgan Stanley (3.51%), Morgan Stanley (3.51%) and First Midwest Bank Trust Division (0.49%). Company insiders that own Quotient stock include Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von and Roland Boyd. View institutional ownership trends for Quotient.

QTNT stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Morgan Stanley, Morgan Stanley, Two Sigma Investments LP, and Tudor Investment Corp Et Al. Company insiders that have sold Quotient company stock in the last year include Jeremy Stackawitz, and Roland Boyd. View insider buying and selling activity for Quotient.

QTNT stock was bought by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, First Midwest Bank Trust Division, DAVENPORT & Co LLC, Premier Asset Management LLC, Castleark Management LLC, Engineers Gate Manager LP, Assenagon Asset Management S.A., and Clearbridge Investments LLC. Company insiders that have bought Quotient stock in the last two years include Frederick Hallsworth, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, and Prondzynski Heino Von. View insider buying and selling activity for Quotient.

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of QTNT stock can currently be purchased for approximately $7.45.

Quotient has a market capitalization of $598.32 million and generates $29.13 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis.

The official website for Quotient is www.quotientbd.com.

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.